NASDAQ:SAVA Cassava Sciences (SAVA) Stock Forecast, Price & News $24.31 -0.17 (-0.69%) (As of 06/9/2023 ET) Add Compare Share Share Today's Range$23.80▼$24.6450-Day Range$21.59▼$27.8852-Week Range$13.84▼$51.59Volume610,491 shsAverage Volume645,012 shsMarket Capitalization$1.01 billionP/E RatioN/ADividend YieldN/APrice Target$54.33 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Cassava Sciences MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside123.5% Upside$54.33 Price TargetShort InterestBearish25.90% of Float Sold ShortDividend StrengthN/ASustainability-0.82Upright™ Environmental ScoreNews Sentiment1.14Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom $0.84 to ($1.33) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.85 out of 5 starsMedical Sector734th out of 987 stocksPharmaceutical Preparations Industry358th out of 482 stocks 3.0 Analyst's Opinion Consensus RatingCassava Sciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 1 hold rating, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $54.33, Cassava Sciences has a forecasted upside of 123.5% from its current price of $24.31.Amount of Analyst CoverageCassava Sciences has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted25.90% of the float of Cassava Sciences has been sold short.Short Interest Ratio / Days to CoverCassava Sciences has a short interest ratio ("days to cover") of 14.4, which indicates bearish sentiment.Change versus previous monthShort interest in Cassava Sciences has recently decreased by 7.47%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCassava Sciences does not currently pay a dividend.Dividend GrowthCassava Sciences does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCassava Sciences has received a 74.60% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for Alzheimer" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Cassava Sciences is -0.82. Previous Next 2.9 News and Social Media Coverage News SentimentCassava Sciences has a news sentiment score of 1.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Cassava Sciences this week, compared to 4 articles on an average week.Search InterestOnly 23 people have searched for SAVA on MarketBeat in the last 30 days. This is a decrease of -44% compared to the previous 30 days.MarketBeat Follows10 people have added Cassava Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 43% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cassava Sciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.00% of the stock of Cassava Sciences is held by insiders.Percentage Held by InstitutionsOnly 25.51% of the stock of Cassava Sciences is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Cassava Sciences are expected to decrease in the coming year, from $0.84 to ($1.33) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cassava Sciences is -11.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cassava Sciences is -11.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCassava Sciences has a P/B Ratio of 4.28. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Cassava Sciences (NASDAQ:SAVA) StockCassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer's disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier in May 1998 and is headquartered in Austin, TX.Read More Receive SAVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cassava Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address SAVA Stock News HeadlinesJune 3, 2023 | msn.comLightning Round: I think SoundHound is a meme stock, says Jim CramerJune 1, 2023 | fool.comCassava Sciences (NASDAQ: SAVA)June 10, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.June 1, 2023 | finance.yahoo.comCassava Sciences to Present at the Jefferies Global Healthcare ConferenceMay 30, 2023 | finance.yahoo.comCassava (SAVA) Up on Progress With Alzheimers Disease StudyMay 23, 2023 | seekingalpha.comCassava Sciences: State Of Play After Earnings - 5 Things To NoteMay 23, 2023 | msn.com3 Biotech Stocks to Avoid Like the PlagueMay 18, 2023 | msn.comUnusual Put Option Trade in Cassava Sciences (SAVA) Worth $338.07KJune 10, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.May 16, 2023 | msn.comCassava Sciences' Simufilam, Anavex's Blarcamesine, And Aricept: Shared Mechanisms Of Action In The Treatment Of Alzheimer's DiseaseMay 14, 2023 | americanbankingnews.comHC Wainwright Weighs in on Cassava Sciences, Inc.'s FY2023 Earnings (NASDAQ:SAVA)May 13, 2023 | americanbankingnews.comHC Wainwright Weighs in on Cassava Sciences, Inc.'s Q2 2023 Earnings (NASDAQ:SAVA)May 12, 2023 | finance.yahoo.comWhy Shares of Cassava Sciences Jumped This WeekMay 11, 2023 | finance.yahoo.comCassava Sciences Completes Patient Dosing in a Randomized Controlled Trial of Simufilam in Alzheimer’s DiseaseMay 11, 2023 | finance.yahoo.comCassava Sciences Stock Clears Benchmark, Hitting 80-Plus RS RatingMay 11, 2023 | americanbankingnews.comCassava Sciences (NASDAQ:SAVA) Shares Up 6%May 10, 2023 | msn.comCassava Sciences' Simufilam Mechanism ValidatedMay 10, 2023 | seekingalpha.comCassava Sciences adds 14% most since SeptemberMay 9, 2023 | investorplace.comWhy Is Cassava Sciences (SAVA) Stock Up 15% Today?May 9, 2023 | msn.comHC Wainwright & Co. Reiterates Cassava Sciences (SAVA) Buy RecommendationMay 8, 2023 | finance.yahoo.comNew Data by Academic Researchers Highlights Biological Activity of Simufilam on Filamin AMay 2, 2023 | marketwatch.com8-K: CASSAVA SCIENCES INCMay 1, 2023 | benzinga.comCassava Sciences Q1 EPS $(0.58) Down From $(0.44) YoYMay 1, 2023 | finance.yahoo.comCassava Sciences Reports Q1 2023 Financial Results and Operating UpdatesApril 26, 2023 | seekingalpha.comBuy Cassava Sciences For Imminent Data ReadoutApril 26, 2023 | finance.yahoo.comCassava Sciences to Present at the 2023 H.C. Wainwright Investor ConferenceApril 18, 2023 | nasdaq.comFirst Week of SAVA April 21st Options TradingSee More Headlines SAVA Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SAVA Company Calendar Last Earnings5/01/2023Today6/10/2023Next Earnings (Estimated)8/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SAVA CUSIPN/A CIK1069530 Webwww.cassavasciences.com Phone(512) 501-2444Fax512-501-0414Employees24Year FoundedN/APrice Target and Rating Average Stock Price Forecast$54.33 High Stock Price Forecast$124.00 Low Stock Price Forecast$11.00 Forecasted Upside/Downside+123.5%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($2.04) Trailing P/E RatioN/A Forward P/E Ratio28.94 P/E GrowthN/ANet Income$-76,250,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-39.12% Return on Assets-37.40% Debt Debt-to-Equity RatioN/A Current Ratio14.02 Quick Ratio14.02 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.68 per share Price / Book4.28Miscellaneous Outstanding Shares41,750,000Free Float37,992,000Market Cap$1.01 billion OptionableNot Optionable Beta-0.15 Key ExecutivesRemi BarbierChairman, President & Chief Executive OfficerEric J. SchoenChief Financial OfficerJames W. KupiecChief Medical OfficerMichael ZamlootSenior Vice President-Technical OperationsGeorge B. ThorntonSenior Vice President-TechnologyKey CompetitorsMorphoSysNASDAQ:MORuniQureNASDAQ:QURERhythm PharmaceuticalsNASDAQ:RYTMEnliven TherapeuticsNASDAQ:ELVNPOINT Biopharma GlobalNASDAQ:PNTView All CompetitorsInsiders & InstitutionsPrelude Capital Management LLCSold 19,500 shares on 6/1/2023Ownership: 0.000%Ameriprise Financial Inc.Bought 25,293 shares on 5/22/2023Ownership: 0.079%JPMorgan Chase & Co.Bought 10,242 shares on 5/18/2023Ownership: 0.119%New York State Common Retirement FundSold 7,786 shares on 5/18/2023Ownership: 0.047%Advisory Services Network LLCBought 9,600 shares on 5/17/2023Ownership: 0.049%View All Insider TransactionsView All Institutional Transactions SAVA Stock - Frequently Asked Questions Should I buy or sell Cassava Sciences stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cassava Sciences in the last twelve months. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" SAVA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SAVA, but not buy additional shares or sell existing shares. View SAVA analyst ratings or view top-rated stocks. What is Cassava Sciences' stock price forecast for 2023? 3 Wall Street analysts have issued 1-year price targets for Cassava Sciences' shares. Their SAVA share price forecasts range from $11.00 to $124.00. On average, they expect the company's share price to reach $54.33 in the next year. This suggests a possible upside of 123.5% from the stock's current price. View analysts price targets for SAVA or view top-rated stocks among Wall Street analysts. How have SAVA shares performed in 2023? Cassava Sciences' stock was trading at $29.54 at the start of the year. Since then, SAVA stock has decreased by 17.7% and is now trading at $24.31. View the best growth stocks for 2023 here. When is Cassava Sciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023. View our SAVA earnings forecast. How were Cassava Sciences' earnings last quarter? Cassava Sciences, Inc. (NASDAQ:SAVA) posted its quarterly earnings results on Monday, May, 1st. The company reported ($0.58) EPS for the quarter, missing analysts' consensus estimates of ($0.56) by $0.02. What ETFs hold Cassava Sciences' stock? ETFs with the largest weight of Cassava Sciences (NASDAQ:SAVA) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH), Invesco Dynamic Biotechnology & Genome ETF (PBE), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), iShares Neuroscience and Healthcare ETF (IBRN), ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Clinical Trials ETF (BBC) and iShares U.S. Pharmaceuticals ETF (IHE).Principal Healthcare Innovators ETF (BTEC). When did Cassava Sciences' stock split? Shares of Cassava Sciences reverse split before market open on Wednesday, May 10th 2017. The 1-7 reverse split was announced on Monday, May 8th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 9th 2017. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split. What other stocks do shareholders of Cassava Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cassava Sciences investors own include Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Novavax (NVAX), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), NIO (NIO), DURECT (DRRX), Tesla (TSLA), OPKO Health (OPK) and Alibaba Group (BABA). What is Cassava Sciences' stock symbol? Cassava Sciences trades on the NASDAQ under the ticker symbol "SAVA." Who are Cassava Sciences' major shareholders? Cassava Sciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.28%), State Street Corp (2.54%), Geode Capital Management LLC (1.82%), Gallacher Capital Management LLC (1.41%), Susquehanna International Group LLP (0.00%) and Charles Schwab Investment Management Inc. (0.70%). Insiders that own company stock include Eric Schoen, James William Kupiec, Remi Barbier, Richard Barry and Sanford Robertson. View institutional ownership trends. How do I buy shares of Cassava Sciences? Shares of SAVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Cassava Sciences' stock price today? One share of SAVA stock can currently be purchased for approximately $24.31. How much money does Cassava Sciences make? Cassava Sciences (NASDAQ:SAVA) has a market capitalization of $1.01 billion. The company earns $-76,250,000.00 in net income (profit) each year or ($2.04) on an earnings per share basis. How can I contact Cassava Sciences? Cassava Sciences' mailing address is 7801 N CAPITAL OF TEXAS HIGHWAY SUITE 260, AUSTIN TX, 78731. The official website for the company is www.cassavasciences.com. The company can be reached via phone at (512) 501-2444, via email at ir@paintrials.com, or via fax at 512-501-0414. This page (NASDAQ:SAVA) was last updated on 6/10/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cassava Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.